Vaccination against Zika virus infection using mosquito NeSt1 protein
使用蚊子 NeSt1 蛋白预防寨卡病毒感染的疫苗
基本信息
- 批准号:10194371
- 负责人:
- 金额:$ 29.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-16 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:Active ImmunizationAdjuvantAedesAluminum HydroxideAnimal ModelAnimalsAntibodiesAntibody ResponseArbovirusesArthropodsBacteriaBiteBloodCellsCulicidaeDengueDengue VirusDevelopmentDoseDrosophila genusFlavivirusGoalsHealthHumanImmune SeraImmune responseImmunityImmunizationImmunizeIndividualInfectionInsectaMediatingMedicalMethodsMusPassive ImmunizationPathogenesisPhasePhysiologicalPost-Translational Protein ProcessingProteinsRecombinant ProteinsRecombinantsRegimenSalivaSalivary ProteinsScheduleSerumSkinStructureSubcutaneous InjectionsSurfaceSystemTimeVaccinationVaccinesViral AntigensViremiaVirusVirus DiseasesWest Nile virusYeastsZIKAZIKV diseaseZIKV infectionZika Virusarthropod-bornebaseefficacy evaluationexperimental studyfeedingglycosylationmortalitymosquito-bornemouse modelneutrophilnovelpathogenphase 2 studypreventprotective effectsuccesssynergismtransmission-blocking vaccinevaccine candidatevaccine developmentvector mosquitoviral transmission
项目摘要
Arthropod-borne viruses (arboviruses) present a substantial threat to human and animal health
worldwide. They are transmitted by hematophagous arthropods, in which mosquitoes are one of
the main transmitters. The mosquito specie, Aedes aegypti, is the primary mosquito vector of
several widely spread arboviruses as zika, dengue or West Nile viruses. Mosquitoes transmit
these pathogens by inoculating virus-infected saliva into host skin during probing and
feeding. This saliva contains over one hundred unique proteins and these proteins have diverse
functions, including facilitating blood feed. Some of these proteins are known to enhance
infectivity and pathogenesis in Zika and other arboviruses by modulating immune responses, and
the development of blocking therapies against them could be a good approach to reduce
infectivity and pathogenesis in the host. In addition, focusing on mosquito proteins as vaccine
targets can overcome the problems associated with the use of viral antigens as a vaccine targets,
due to their high variability.
In this proposal, we will develop a novel transmission-blocking vaccine against Zika virus (ZIKV)
by targeting A. aegypti bacteria responsive protein 1 (AgBR1) and A. aegypti neutrophil
stimulating factor 1 (NeSt1) salivary gland protein. Using a yeast surface display screen, we
identified a set of A. aegypti salivary proteins that react with sera from mice repeatedly bitten by
A. aegypti mosquitoes. Passive immunization with antiserum against two of these proteins,
AgBR1 and NeSt1, resulted in significantly more survival in mice infected with ZIKV by mosquito
bite. Simultaneous passive immunization with both antisera demonstrated a synergy resulting in
higher survival than expected from the individual treatments.
Based on these results, in this proposal we intend to carefully examine the protective effects of
blocking the mosquito AgBR1 and NeSt1 proteins in preventing severe mosquito-borne ZIKV
infection in mice. We will develop a strategy for actively immunizing mice against both proteins
towards the development of a vaccine for use in humans. The success of this approach also offers
a functional paradigm for developing vaccines against other flaviviruses and other arthropod-
borne pathogens of medical importance.
节肢动物传播的病毒(虫媒病毒)对人类和动物的健康构成重大威胁
国际吧它们是由吸血节肢动物传播的,蚊子是其中之一。
主要的发射机。蚊子种类埃及伊蚊是疟疾的主要蚊媒。
几种广泛传播的虫媒病毒,如寨卡病毒、登革热病毒或西尼罗河病毒。蚊子传播
这些病原体在探测过程中通过感染了HPV的唾液进入宿主皮肤,
喂食这种唾液含有超过100种独特的蛋白质,这些蛋白质具有不同的
功能,包括促进血液供给。其中一些蛋白质可以增强
通过调节免疫反应,感染寨卡病毒和其他虫媒病毒,
针对它们的阻断疗法的发展可能是一种很好的方法,
在宿主中的传染性和致病性。此外,将蚊子蛋白作为疫苗
靶可以克服与使用病毒抗原作为疫苗靶相关的问题,
由于其高度可变性。
在这项提案中,我们将开发一种针对寨卡病毒(ZIKV)的新型传播阻断疫苗
以A为目标。埃及伊蚊细菌应答蛋白1(AgBR 1)和埃及伊蚊(A.埃及嗜中性粒细胞
刺激因子1(NeSt1)唾液腺蛋白。使用酵母表面显示屏,我们
确定了一组A。埃及伊蚊唾液蛋白与反复叮咬的小鼠血清反应,
A.埃及蚊子。用抗这些蛋白质中的两种的抗血清进行被动免疫,
AgBR 1和NeSt 1在通过蚊子感染ZIKV的小鼠中导致显著更多的存活
咬人的用两种抗血清同时进行被动免疫证明了协同作用,
存活率高于个体治疗的预期。
基于这些结果,在本提案中,我们打算仔细研究
阻断蚊子AgBR1和NeSt1蛋白,预防严重的蚊子传播的ZIKV
感染小鼠。我们将开发一种主动免疫小鼠对抗这两种蛋白质的策略
开发用于人类的疫苗。这种方法的成功还提供了
一种用于开发针对其他黄病毒和其他节肢动物的疫苗的功能范例,
具有医学重要性的病原体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michel Ledizet其他文献
Michel Ledizet的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michel Ledizet', 18)}}的其他基金
Vaccination against Zika virus infection using mosquito NeSt1 protein
使用蚊子 NeSt1 蛋白预防寨卡病毒感染的疫苗
- 批准号:
10081573 - 财政年份:2020
- 资助金额:
$ 29.39万 - 项目类别:
An antigen-detection assay to diagnose Babesia microti infection
诊断田鼠巴贝斯虫感染的抗原检测方法
- 批准号:
10403621 - 财政年份:2018
- 资助金额:
$ 29.39万 - 项目类别:
An antigen-detection assay to diagnose Babesia microti infection
诊断田鼠巴贝斯虫感染的抗原检测方法
- 批准号:
10082042 - 财政年份:2018
- 资助金额:
$ 29.39万 - 项目类别:
An antigen-detection assay to diagnose Babesia microti infection
诊断田鼠巴贝斯虫感染的抗原检测方法
- 批准号:
10200003 - 财政年份:2018
- 资助金额:
$ 29.39万 - 项目类别:
Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens
使用体内表达抗原诊断早期莱姆疏螺旋体病
- 批准号:
8876556 - 财政年份:2014
- 资助金额:
$ 29.39万 - 项目类别:
A Lyme disease vaccine using newly identified in-vivo expressed antigens
使用新鉴定的体内表达抗原的莱姆病疫苗
- 批准号:
8455815 - 财政年份:2013
- 资助金额:
$ 29.39万 - 项目类别:
A Lyme disease vaccine using newly identified in-vivo expressed antigens
使用新鉴定的体内表达抗原的莱姆病疫苗
- 批准号:
8601286 - 财政年份:2013
- 资助金额:
$ 29.39万 - 项目类别:
Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens
使用体内表达抗原诊断早期莱姆疏螺旋体病
- 批准号:
8782201 - 财政年份:2012
- 资助金额:
$ 29.39万 - 项目类别:
Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens
使用体内表达抗原诊断早期莱姆疏螺旋体病
- 批准号:
8315248 - 财政年份:2012
- 资助金额:
$ 29.39万 - 项目类别:
A serologic assay to measure successful Lyme borreliosis antibiotic therapy
测量莱姆疏螺旋体病抗生素治疗是否成功的血清学检测
- 批准号:
8715103 - 财政年份:2010
- 资助金额:
$ 29.39万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 29.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 29.39万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 29.39万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 29.39万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 29.39万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 29.39万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 29.39万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 29.39万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 29.39万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 29.39万 - 项目类别: